## Abstract Platelet‐derived growth factor (PDGF) plays an important role in tissue regeneration and wound repair. However, the lack of effective delivery and the efficient targeting specificity limits its clinical applications. Here, heparin possessing PDGF binding domain was crosslinked to the co
Controlled delivery of platelet-rich plasma-derived growth factors for bone formation
✍ Scribed by Helen H. Lu; Jennifer M. Vo; Hsin Sheila Chin; Jeffrey Lin; Matthew Cozin; Rick Tsay; Sidney Eisig; Regina Landesberg
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 343 KB
- Volume
- 86A
- Category
- Article
- ISSN
- 1549-3296
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Platelet‐rich plasma (PRP) represents an autologous source of growth factors essential for bone regeneration. The clinical efficacy of PRP is, however, unpredictable, and this is likely due to the inefficient and inconsistent delivery of PRP‐derived growth factors. Previous investigations have shown that current methods of PRP preparation result in a premature release of the relevant bone stimulatory factors. As successful bone regeneration requires multiple factors presented in a physiologic temporal and spatial cascade, the objective of this study is to control the bioavailability of PRP‐derived growth factors using a hydrogel carrier system. Specifically, the release of platelet‐derived growth factor, transforming growth factor beta‐1, and insulin‐like growth factor from two types of alginate carriers was compared over time. The effects of the released factors on the growth and alkaline phosphatase (ALP) activity of human osteoblast‐like cells were also evaluated. It was found that factor release profiles varied as function of carrier type, and binding of growth factors to the alginate matrix also modulated their release. The bioactivity of released factors was maintained in vitro and they promoted cell proliferation and ALP activity. These results demonstrate the potential of this autologous multifactor delivery system for controlling the bioavailability of PRP‐derived factors. Future studies will focus on optimizing this system to increase the clinical efficacy of PRP by matching the distribution and temporal sequencing of PRP‐derived factors to the bone healing cascade. © 2008 Wiley Periodicals, Inc. J Biomed Mater Res 2008
📜 SIMILAR VOLUMES
## Abstract The purpose of this study was to evaluate effects of human platelet‐rich plasma (PRP)‐containing fragmin/protamine microparticles (F/P MPs) as a protein carrier on neovascularization and granulation tissue formation. Frozen and thawed PRP contains high concentrations of various growth f